Calmark is developing a POC-test to help assess disease severity for patients with COVID-19 patients
The Board of Directors of Calmark Sweden AB has today resolved to prioritize the development of a diagnostic point-of-care (POC) test for the lactate dehydrogenase biomarker (LDH) aimed at adult patients with COVID-19. Several studies have demonstrated that LDH levels can predict the severity and mortality of the disease. Since the time aspect of COVID-19 products is of paramount importance, this test will be developed in parallel with the tests for newborns; Neo-LDH and Neo-Glucose.In the ongoing COVID-19 coronavirus disease pandemic, more than 9 million cases of infection have been